Levetiracetam
- Generic Name
- Levetiracetam
- Brand Names
- Elepsia, Keppra, Matever, Roweepra, Spritam, Levetiracetam Accord, Levetiracetam Teva, Levetiracetam Actavis, Levetiracetam ratiopharm, Levetiracetam Sun, Levetiracetam Actavis Group, Levetiracetam Hospira
- Drug Type
- Small Molecule
- Chemical Formula
- C8H14N2O2
- CAS Number
- 102767-28-2
- Unique Ingredient Identifier
- 44YRR34555
- Background
Levetiracetam is a drug within the pyrrolidine class that is used to treat various types of seizures stemming from epileptic disorders. It was first approved for use in the United States in 1999 and is structurally and mechanistically unrelated to other anti-epileptic drugs (AEDs). Levetiracetam possesses a wide therapeutic index and little-to-no potential to produce, or be subject to, pharmacokinetic interactions - these characteristics make it a desirable choice over other AEDs, a class of drugs notorious for having generally narrow therapeutic indexes and a propensity for involvement in drug interactions.
- Indication
Levetiracetam is indicated as an adjunctive therapy in the treatment of partial onset seizures in epileptic patients who are one month of age and older. Additionally, it is indicated as an adjunct in the treatment of myoclonic seizures in patients with juvenile myoclonic epilepsy who are 12 years of age and older, and in primary generalized tonic-clonic seizures in patients with idiopathic generalized epilepsy who are 6 years of age and older.
Levetiracetam is also available as an orally dissolvable tablet that is indicated as an adjunct in the treatment of partial onset seizures in patients with epilepsy who are 4 years of age and older and weigh more than 20kg.
- Associated Conditions
- Epilepsies, Generalized Tonic-Clonic Seizures, Partial-Onset Seizures, Myoclonic seizures
- Associated Therapies
- -
Levetiracetam for Benign Rolandic Epilepsy
- Conditions
- Epilepsy
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2009-03-27
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 6
- Registration Number
- NCT00181116
- Locations
- 🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States
Levetiracetam in the Treatment of Neuroleptic-induced Tardive Dyskinesia
- Conditions
- Dyskinesia, Medication-induced
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2013-12-06
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 70
- Registration Number
- NCT00175955
A Placebo-controlled Study of Levetiracetam In Children (1mo to 4yrs of Age) With Partial Onset Seizures.
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2020-10-01
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 116
- Registration Number
- NCT00175890
Levetiracetam Versus Standard Antiepileptic Drugs (Carbamazepine and Valproate) Used as Monotherapy in Patients With Newly Diagnosed Epilepsy
- Conditions
- Epilepsy
- Interventions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2015-03-17
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 1701
- Registration Number
- NCT00175903
Levetiracetam Treatment in Adult Subjects With Parkinson's Disease Experiencing Troublesome Dyskinesias
- Conditions
- Idiopathic Parkinson Disease
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2013-12-06
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 30
- Registration Number
- NCT00160576
Study to Evaluate the Safety and Efficacy of Levetiracetam in Patients Suffering From Idiopathic Generalized Epilepsy With Primary Generalized Tonic-clonic Seizures
- Conditions
- Generalized Convulsive Epilepsy
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2013-11-26
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 154
- Registration Number
- NCT00160550
A Study to Determine if Levetiracetam Will Assist Those Suffering From Chronic Idiopathic Axonal Polyneuropathy.
- Conditions
- Chronic Idiopathic Axonal Polyneuropathy
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2008-01-11
- Lead Sponsor
- Vanderbilt University
- Target Recruit Count
- 30
- Registration Number
- NCT00156689
- Locations
- 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States
Open Label Safety and Efficacy Study of Levetiracetam in Korean Patients With Epilepsy
- Conditions
- Epilepsy, Partial
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2013-11-26
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 100
- Registration Number
- NCT00160628
A 16 Week Study Evaluating Levetiracetam in the Treatment of Post Herpetic Neuralgia (PHN)
- Conditions
- Neuralgia, Postherpetic
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2013-11-26
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 170
- Registration Number
- NCT00160511
Follow-up Study of L059 (Levetiracetam) in Epileptic Patients With Partial Onset Seizures by Open Label Method
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2019-06-10
- Lead Sponsor
- UCB Japan Co. Ltd.
- Target Recruit Count
- 154
- Registration Number
- NCT00160615
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.